Imunon (NASDAQ:IMNN) General Counsel Sells $20,650.00 in Stock

Imunon, Inc. (NASDAQ:IMNN) General Counsel Susan Eylward sold 11,800 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $1.75, for a total value of $20,650.00. Following the transaction, the general counsel owned 2,896 shares of the company’s stock, valued at $5,068. This trade represents a 80.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Imunon Stock Up 0.6%

Imunon stock traded up $0.01 during mid-day trading on Monday, reaching $1.80. 56,995 shares of the company’s stock were exchanged, compared to its average volume of 73,057. The company has a market cap of $7.56 million, a P/E ratio of -0.35 and a beta of 1.95. Imunon, Inc. has a twelve month low of $1.70 and a twelve month high of $11.19. The company has a fifty day moving average of $2.34 and a 200-day moving average of $3.00.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.38. Equities research analysts expect that Imunon, Inc. will post -3.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Imunon

A number of institutional investors and hedge funds have recently modified their holdings of IMNN. Armistice Capital LLC acquired a new position in shares of Imunon during the 4th quarter worth $1,017,000. DRW Securities LLC grew its stake in Imunon by 6.9% in the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock valued at $224,000 after acquiring an additional 3,803 shares during the last quarter. Finally, Riverview Capital Advisers LLC grew its stake in Imunon by 193.3% in the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock valued at $176,000 after acquiring an additional 22,649 shares during the last quarter. Institutional investors and hedge funds own 4.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IMNN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a research report on Tuesday, April 21st. Maxim Group set a $10.00 target price on shares of Imunon and gave the company a “buy” rating in a report on Friday, April 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.